

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Shewchuk *et al.*

Confirmation No.: 7149

Application No.: 10/543,046

Group Art Unit: 1656

Filed: July 21, 2005

Examiner: David J. Steadman

For: METHOD OF INHIBITOR DESIGN USING A 3-D STRUCTURE OF ErbB4 KINASE  
(title as amended)

---

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

STATEMENT TO SUPPORT FILING AND SUBMISSION  
IN ACCORDANCE WITH 37 CFR §§1.821-1.825

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 CFR §1.821(g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Please replace the Sequence Listing submitted on June 6, 2007 with the replacement listing provided herewith.

Respectfully submitted

Date: 9/27/2008

Kathryn L. Coulter  
Kathryn L. Coulter  
Attorney of Record  
Registration No. 45,889

Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1467  
Facsimile: (919) 483-7988